On April 8 2026, the U.S. Food and Drug Administration cleared Waters Corporation’s Onclarity HPV Self‑Collection Kit for at‑home use, allowing consumers to collect cervical cancer screening samples at home and ship them to a laboratory for analysis. The kit is used in conjunction with the BD Onclarity HPV Assay, which detects all high‑risk, carcinogenic HPV genotypes and is the only FDA‑approved assay that identifies six individual and three pooled results.
The clearance removes a regulatory hurdle that had delayed at‑home screening options, creating a new revenue stream for Waters’ Advanced Diagnostics division and positioning the company to capture a growing market for decentralized diagnostics. By enabling self‑collection, the kit addresses a critical public‑health need, as roughly 60% of cervical cancer cases occur in individuals who are unscreened or under‑screened.
The at‑home HPV testing market is expanding rapidly, driven by increased awareness of HPV’s link to cervical cancer and the integration of HPV testing into routine screening. The self‑sampling segment is expected to grow as insurers cover the kit under private insurance, Medicaid, and Medicare, and as pharmacists play a role in counseling patients on its use and follow‑up care.
While other companies offer at‑home HPV self‑collection kits, Waters’ product stands out because the BD Onclarity assay uniquely provides six individual genotypes and three pooled results, giving clinicians more detailed information about a patient’s risk profile. This extended genotyping capability is a key differentiator in a competitive landscape that includes other primary HPV tests and self‑collection solutions.
The FDA clearance was supported by data from the National Institutes of Health’s National Cancer Institute “Last Mile” Initiative SHIP trial, which demonstrated the assay’s accuracy and reliability in a real‑world self‑collection setting. The trial’s outcomes were a critical factor in the agency’s decision to approve the kit for at‑home use.
The kit is expected to be available by prescription in the coming months, with Waters actively establishing nationwide partnerships to ensure broad access. Pharmacists are anticipated to play a key role in dispensing the kit and providing patient education, further expanding the product’s reach.
Jeff Andrews, M.D., FRCSC, Vice President of Medical Affairs for Waters Advanced Diagnostics, said, “Expanding access to screening is one of the most important steps we can take to prevent cervical cancer, and at‑home HPV self‑collection is a game changer for making screening easier to complete.” Jianqing Bennett, Senior Vice President of Waters Advanced Diagnostics, added, “U.S. FDA clearance of the Onclarity Self‑Collection Kit for at‑home use marks a meaningful step toward removing today’s primary barriers to screening, and supporting more personalized care.”
The clearance not only creates a new revenue stream for Waters but also advances health equity by providing a convenient, private screening option for underserved populations, including African American women who experience higher cervical cancer incidence and mortality rates. By expanding access, Waters is positioned to capture a significant share of the growing self‑sampling market while contributing to the broader public‑health goal of reducing cervical cancer burden.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.